- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02672787
A ED-based Intervention to Improve Antihypertensive Adherence
A Randomized, ED-based Intervention to Improve Antihypertensive Adherence
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
More than 37 million Americans have uncontrolled hypertension, with associated costs of $93.5 billion in 2010. Emergency department visits for hypertension rose 25% from 2006 to 2011. According to the Centers for Disease Control and Prevention, "improved hypertension control…require[s] an expanded effort and an increased focus on blood pressure from health-care systems, clinicians, and individuals."
ED visits among patients with uncontrolled blood pressure are often missed opportunities for the ED to serve as an additional healthcare touchpoint and opportunity to impact chronic disease control by complementing chronic care. The ED is a common access point into the healthcare system, with more than 120 million visits annually among 20% of Americans. ED visits specifically for hypertension are also common, with more than 5 million visits per year and rising rapidly as more newly insured and chronically ill patients seek ED care. Elevated blood pressure (BP) is noted in 15-25% of all ED visits and cannot be attributed solely to pain. An ED-based intervention places focus on patients who are at increased risk for poor clinical outcomes and who are likely to gain benefit from interventions.
Medication adherence, or taking medications as prescribed, is crucial for BP control. Until now, measuring antihypertensive adherence in the ED has been limited to self-report, which is influenced by recall and social desirability biases and lack of an established patient-provider relationship. As a result, little is known regarding factors related to antihypertensive adherence or optimal interventions to improve adherence among ED patients. This project utilizes a validated mass spectrometry plasma assay as a measure of antihypertensive adherence to overcome these limitations. This tool will be combined with a conceptual framework in order to test our understanding of how adherence relates to blood pressure control among ED patients. The conceptual framework is based on work by Krousel-Wood, Bosworth, Murray, and Gellad and is grounded in the Information-Motivation-Behavioral Skills model of health behavior change, Social Cognitive Theory, and successful clinic-based adherence interventions.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- <6 hours since initial evaluation by a treating physician in the ED
- Prescribed only antihypertensives detected by the mass spectrometry plasma assay
- Prescribed at least 1 antihypertensive detected by the mass spectrometry plasma assay
- Functioning peripheral IV, available left over (after clinical testing) blood, or willing to undergo venipuncture to obtain blood
- Anticipated discharge from the ED, per ED attending
- Elevated blood pressure in the ED, including triage systolic blood pressure of at least 140 mmHg or triage diastolic blood pressure of at least 90 mmHg, or 2 or more elevated BP measurements after triage (>=140/90 mmHg)
- Able and willing to complete ~45 minutes of surveys, discussion in the ED as well as return for 2 follow up visits (i.e., no plans to move away or change medical providers in the next 6 months)
- Willing to receive reminder messages via chosen method (e.g., text, phone call, or letter) for 45 days after enrollment
- Has a healthcare provider who prescribes blood pressure medication, defined as having had a clinic visit within the past year
- Age ≥21 years and <85 years
Exclusion Criteria:
- Received vasoactive medication (including prescribed BP medications) in the ED prior to enrollment
- Previously enrolled
- End stage renal disease or on hemodialysis
- Known pregnancy or anticipated pregnancy within 6 months
- Sepsis, acute blood loss, acute alcohol withdrawal, or inability to tolerate medications in the 24 hours prior to arrival
- Unable to provide informed consent (e.g., altered mental status, chronic dementia, prisoner, or inability to speak/understand English)
- Enrolled in home health or other chronic care coordination management plan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ED usual care plus education
|
Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
|
Experimental: Intervention
Subjects will receive the ED-based behavioral intervention
|
Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-month Blood Pressure
Time Frame: 1-month
|
The primary outcome is change in Blood Pressure, measured by BPTru, one month after enrollment.
|
1-month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-month Change in Adherence Measured by Assay
Time Frame: 1-month
|
Change in adherence as measured by the plasma assay.
|
1-month
|
1-month Change in Adherence Measured by Patient-report
Time Frame: 1-month
|
Change in adherence as measured by patient-report.
|
1-month
|
3-month Change in Blood Pressure
Time Frame: 3-month
|
3-month Change in Blood Pressure, measured by BPTru
|
3-month
|
3-month Change in Adherence Measured by Patient-report
Time Frame: 3-month
|
BP and patient-reported adherence will evaluate longer-term impact of the intervention.
|
3-month
|
Proportion of patients with controlled BP
Time Frame: 1-month
|
Compare the proportion of patients who achieve controlled BP at 1-month
|
1-month
|
Proportion of patients with controlled BP
Time Frame: 3-month
|
Compare the proportion of patients who achieve controlled BP at 3-month
|
3-month
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association of death with antihypertensive adherence measured by the blood mass spectrometry assay
Time Frame: 1 year, minimum
|
Evaluate whether adherence (by assay) predicts mortality among patients enrolled in the study
|
1 year, minimum
|
Association of death with antihypertensive adherence measured by patient report
Time Frame: 1 year, minimum
|
Evaluate whether adherence (by patient report) predicts mortality among patients enrolled in the study
|
1 year, minimum
|
Association of repeat ED visits with antihypertensive adherence measured by the blood mass spectrometry assay
Time Frame: 1 year, minimum
|
Evaluate whether adherence (by assay) predicts repeat ED visits, in survival analysis
|
1 year, minimum
|
Association of hospitalization with antihypertensive adherence measured by the blood mass spectrometry assay
Time Frame: 1 year, minimum
|
Evaluate whether adherence (by assay) predicts hospitalization, in survival analysis
|
1 year, minimum
|
Impact of the intervention on patient trust, measured by the Primary Care Assessment Survey (PCAS), at 3 months, by study arm
Time Frame: 3 months
|
Evaluate whether the intervention was associated with change in the trajectory of patient trust over 3 months (longitudinal analysis)
|
3 months
|
Relationship between intervention vs. usual care plus education on the change in measured side effects of antihypertensives (TOMHS survey) at 3 months
Time Frame: 3 months
|
Evaluate whether the intervention or improvement in adherence were associated with higher patient-reported side effects, measured by the TOMHS, at 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Candace McNaughton, MD, Vanderbilt University
Publications and helpful links
General Publications
- Spieker AJ, Nelson LA, Rothman RL, Roumie CL, Kripalani S, Coco J, Fabbri D, Levy P, Collins SP, Wang T, Liu D, McNaughton CD. Feasibility and Short-Term Effects of a Multi-Component Emergency Department Blood Pressure Intervention: A Pilot Randomized Trial. J Am Heart Assoc. 2022 Mar;11(5):e024339. doi: 10.1161/JAHA.121.024339. Epub 2022 Feb 23.
- Nelson LA, Spieker AJ, Kripalani S, Rothman RL, Roumie CL, Coco J, Fabbri D, Levy P, Collins SP, McNaughton CD. User preferences for and engagement with text messages to support antihypertensive medication adherence: Findings from a pilot study evaluating an emergency department-based behavioral intervention. Patient Educ Couns. 2022 Jun;105(6):1606-1613. doi: 10.1016/j.pec.2021.10.011. Epub 2021 Oct 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 151384
- K23HL125670 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on ED usual care plus education
-
VA Connecticut Healthcare SystemCompletedDiabetic Peripheral Neuropathic PainUnited States
-
Emory UniversityNational Institute of Nursing Research (NINR)Completed
-
McGill University Health Centre/Research Institute...Diabetes CanadaActive, not recruitingGlucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic DiseaseCanada
-
Duke UniversityActive, not recruitingPost-Lung TransplantationUnited States
-
University of RochesterCompletedAsthmaUnited States
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedObesity, ChildhoodUnited States
-
Altoosi University CollegeBabylon UniversityUnknownCerebral Palsy | Cancer | HIV/AIDS | Muscular Dystrophy | Cystic Fibrosis | Cardiac Anomaly | Batten's DiseaseIraq
-
Suzanna ZickUniversity of MichiganTerminatedQuality of Life | Fatigue | Lupus Erythematosus, Systemic | Sleep | Pain, ChronicUnited States
-
University of PennsylvaniaNational Cancer Institute (NCI); American Cancer Society, Inc.CompletedFibrosis | Head and Neck Cancer | LymphedemaUnited States
-
University of California, Los AngelesPatient-Centered Outcomes Research Institute; Brown University; Duke University; University of Utah and other collaboratorsRecruiting